scholarly journals Targeting GH-1 splicing as a novel pharmacological strategy for growth hormone deficiency type II

2017 ◽  
Vol 124 ◽  
pp. 1-9 ◽  
Author(s):  
Maria Consolata Miletta ◽  
Christa E. Flück ◽  
Primus-E. Mullis
2009 ◽  
Vol 94 (12) ◽  
pp. 4728-4734 ◽  
Author(s):  
Rizwan Hamid ◽  
John A. Phillips ◽  
Cindy Holladay ◽  
Joy D. Cogan ◽  
Eric D. Austin ◽  
...  

2012 ◽  
Vol 77 (3) ◽  
pp. 200-204 ◽  
Author(s):  
Zoran Gucev ◽  
Velibor Tasic ◽  
Liljana Saranac ◽  
Heike Stobbe ◽  
Jürgen Kratzsch ◽  
...  

2013 ◽  
Vol 80 (6) ◽  
pp. 390-396 ◽  
Author(s):  
M.J.E. Kempers ◽  
S.N. van der Crabben ◽  
M. de Vroede ◽  
J. Alfen-van der Velden ◽  
R.T. Netea-Maier ◽  
...  

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S107-S112 ◽  
Author(s):  
HERWIG FRISCH ◽  
JOHN A. PHILLIPS

Abstract An 11 year old Austrian boy with isolated growth hormone deficiency type I A is described. On institution of GH therapy at the age of 2 2/12 years there was only a short growth response and anti-GH-antibodies with high binding capacity were detected, and growth was inhibited. Examination of the nuclear DNA by restriction endonuclease analysis demonstrated a defect of the GH-N gene in the patient. The results suggest the deletion in this Austrian family is different from that seen in other patients. The parents were heterozygous for the deletion and had a subnormal GH response to stimulation with arginine, but their somatomedin-C concentrations and their heights were normal. The patients' sister was of normal height, hormone analyses were normal, and the GH-N gene was not affected.


Sign in / Sign up

Export Citation Format

Share Document